Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$83.74M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
2954.91%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$362.3M
Q3 2024
Cash
Q3 2024
P/E
-9.288
Nov 29, 2024 EST
Free Cash Flow
-$64.98M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $17.43M $15.92M $5.652M $2.094M $1.332M
YoY Change 9.47% 181.65% 169.91% 57.21%
% of Gross Profit
Research & Development $62.52M $43.01M $20.64M $7.203M $1.786M
YoY Change 45.36% 108.41% 186.49% 303.3%
% of Gross Profit
Depreciation & Amortization $353.0K $296.0K $140.0K $47.00K $8.000K
YoY Change 19.26% 111.43% 197.87% 487.5%
% of Gross Profit
Operating Expenses $79.95M $58.93M $26.29M $9.297M $3.122M
YoY Change 35.67% 124.16% 182.76% 197.79%
Operating Profit -$79.95M -$58.93M -$26.29M -$9.297M
YoY Change 35.67% 124.16% 182.76%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $10.85M $3.652M $13.00K -$2.000K -$2.000K
YoY Change 197.1% 27992.31% -750.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$39.00K $3.602M -$6.000K -$39.00K -$941.0K
YoY Change -101.08% -60133.33% -84.62% -95.86%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$69.13M -$55.33M -$26.29M -$9.336M -$4.065M
YoY Change 24.96% 110.41% 181.64% 129.67%
Income Tax $0.00 $2.000K $1.000K $1.000K
% Of Pretax Income
Net Earnings -$69.13M -$55.33M -$26.29M -$9.336M -$4.065M
YoY Change 24.96% 110.41% 181.64% 129.67%
Net Earnings / Revenue
Basic Earnings Per Share -$1.62 -$1.32 -$1.91
Diluted Earnings Per Share -$1.62 -$1.32 -$634.5K -$236.9K -$103.2K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $203.5M $251.2M $302.2M $15.22M $108.0K
YoY Change -19.01% -16.87% 1884.91% 13996.3%
Cash & Equivalents $58.01M $251.2M $302.2M $15.22M $108.0K
Short-Term Investments $145.5M
Other Short-Term Assets $8.202M $6.075M $1.875M $57.00K $19.00K
YoY Change 35.01% 224.0% 3189.47% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $211.7M $257.3M $304.1M $15.28M $127.0K
YoY Change -17.73% -15.38% 1889.77% 11932.28%
Property, Plant & Equipment $8.154M $3.543M $2.089M $466.0K $276.0K
YoY Change 130.14% 69.6% 348.28% 68.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.032M $5.350M $555.0K $264.0K $125.0K
YoY Change 12.75% 863.96% 110.23% 111.2%
Total Long-Term Assets $14.19M $8.893M $2.644M $730.0K $401.0K
YoY Change 59.52% 236.35% 262.19% 82.04%
Total Assets $225.9M $266.2M $306.7M $16.01M $528.0K
YoY Change
Accounts Payable $4.662M $1.145M $599.0K $664.0K $327.0K
YoY Change 307.16% 91.15% -9.79% 103.06%
Accrued Expenses $10.67M $4.556M $3.017M $1.185M $486.0K
YoY Change 134.22% 51.01% 154.6% 143.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.000K $17.00K
YoY Change -47.06%
Total Short-Term Liabilities $15.33M $5.701M $3.616M $1.858M $5.155M
YoY Change 168.95% 57.66% 94.62% -63.96%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.262M $2.651M $1.348M $140.0K $114.0K
YoY Change 136.21% 96.66% 862.86% 22.81%
Total Long-Term Liabilities $6.262M $2.651M $1.348M $140.0K $114.0K
YoY Change 136.21% 96.66% 862.86% 22.81%
Total Liabilities $21.60M $8.352M $4.964M $1.998M $5.269M
YoY Change 158.56% 68.25% 148.45% -62.08%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 42.70M 41.88M 13.78M
Diluted Shares Outstanding 42.70M 41.88M 13.78M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $777.77 Million

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 49 full-time employees. The company went IPO on 2021-09-15. The company is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Industry: Pharmaceutical Preparations Peers: Aldeyra Therapeutics, Inc. ALPINE IMMUNE SCIENCES, INC. MIMEDX GROUP, INC. Atara Biotherapeutics, Inc. Biomea Fusion, Inc. BioXcel Therapeutics, Inc. Foghorn Therapeutics Inc. Prelude Therapeutics Inc Vigil Neuroscience, Inc.